STTR Phase I: Neuromodulation by Electromagnetic (EM) Energy-Induced Hypersound

STTR 第一阶段：通过电磁 (EM) 能量诱导超声进行神经调节

• 批准号: 2136383
• 负责人: Chad Andresen
• 金额: $ 25.6万
• 依托单位: HYPERSOUND MEDICAL, INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-15 至 2023-11-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2136383&HistoricalAwards=false
• 关键词: STTR; Phase; Neuromodulation; Electromagnetic; EM

The broader impact of this Small Business Technology Transfer (STTR) Phase I project proposes to develop a new way to block pain in the human body. This new technology offers the potential for a novel, less invasive, lower cost, non-addicting solution to pain relief. The project develops a device to be applied near or on the skin, significantly penetrating the tissue to inhibit pain. The primary market is to provide relief from back pain, which affects more than 100 M Americans. Other potential markets include pain suppression from peripheral wounds, neuralgias, migraine, cancer, diabetes-related neuropathies, and degenerative diseases, such as the rheumatoid group. This Small Business Technology Transfer Phase I Project proposes a new approach to noninvasively modulate selected neural tissues to block pain by known principles of neurological competitive inhibition. The technology employs electromagnetic energy in a novel electrostrictive mode of action within the dielectric nature of cellular media to remotely evoke ultrasound as well as higher frequency hypersound forces in-situ. These induced forces are hypothesized to result in biological effects through the well-known action of cellular stretch activation. This project will further develop instrumentation to produce unique microwave device designs and determine the effects of microwave variables on neuromodulation. The research institution will apply the developed instrumentation on rat and neuronal cell models to define the important operating parameters for ensuring therapeutic safety and efficacy.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小企业技术转让(STTR)第一阶段项目的更广泛影响建议开发一种新的方法来阻止人体内的疼痛。这项新技术为一种新的、侵入性更小、成本更低、不会上瘾的止痛解决方案提供了可能性。该项目开发了一种设备，可以贴在皮肤附近或皮肤上，显著穿透组织以抑制疼痛。主要市场是缓解背部疼痛，背部疼痛影响着1亿多美国人。其他潜在市场包括外周创伤、神经痛、偏头痛、癌症、糖尿病相关神经疾病和退行性疾病(如类风湿性疾病)的止痛。这个小企业技术转移第一阶段项目提出了一种新的方法，通过已知的神经竞争抑制原理来非侵入性地调节选定的神经组织来抑制疼痛。该技术在蜂窝介质的介电性质内以一种新颖的电致伸缩作用模式使用电磁能量，以远程在现场唤起超声波和更高频率的超声力。这些诱导力被假设为通过众所周知的细胞伸展激活作用而产生生物效应。该项目将进一步开发仪器，以产生独特的微波设备设计，并确定微波变量对神经调节的影响。该研究机构将在大鼠和神经细胞模型上应用开发的仪器来定义确保治疗安全性和有效性的重要操作参数。这一奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。